Asset Details
Do you wish to reserve the book?
The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up
Do you wish to request the book?
The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up
2025
Overview
Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis in children, causing significant joint inflammation and complications. This study evaluates the incidence, prevalence, and treatment patterns of JIA in Taiwan, focusing on biologic therapy.
A retrospective observational study utilized data from the National Health Insurance Research Database (NHIRD) for the period 2011-2020. Patients diagnosed with JIA were identified, and the annual incidence and prevalence rates were calculated. Treatment patterns, particularly regarding biologics, were assessed. Subgroup analysis compared patients diagnosed with spondyloarthritis (SpA) versus non-SpA within the JIA cohort.
Two thousand and thirty-three JIA patients were included. The annual prevalence ranged from 18.0 to 24.2 per 100,000 populations under 16 years old, with an incidence of 5.22 to 6.57 per 100,000. A male predominance was noted (male-to-female ratio: 1.08-1.52:1). The JIA-SpA subgroup comprised 49.2% of the JIA cohort. Compared to Non-SpA patients, the JIA-SpA subgroup showed male predominance (70.7% vs. 44.4%, p<0.0001), later age of onset, and lower biologic use (15.2% vs. 23.1%, p<0.001). Tumor necrosis factor alpha inhibitors were the most used biologics, with a continuation rate of 49.1%. Switching occurred in 13.2% of patients, mostly without interruption within a treatment gap of 60 days. Discontinuation without subsequent biologic therapy was observed in 9.5% of patients, while 28.2% restarted therapy after a treatment interruption of more than 60 days.
This study highlights the epidemiological characteristics and treatment patterns for JIA in Taiwan, focusing on biologic therapies. Most patients maintained consistent biologics, with a small proportion able to discontinue them, emphasizing the need for region-specific management strategies.
Publisher
Frontiers Media SA,Frontiers Media S.A
